Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on North Dakota Healthcare Newswire.
Press releases published on July 10, 2025
Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership
GlobeNewswire
·
July 10, 2025
SEATTLE, July 10, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 AI Labs, LLC, a wholly owned subsidiary of Fifty 1 Labs, Inc. (OTC: FITY), in collaboration with premier academic institutions including Stanford University, Duke University, McMaster University …
BioStem Technologies to Present at the Advanced Wound Care Summit in Boston on July 15, 2025, at 2:00 PM ET
GlobeNewswire
·
July 10, 2025
POMPANO BEACH, Fla., July 10, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that …
SS Innovations Announces Completion of World’s First Robotic Telesurgery for Weight Loss with the Company’s SSi Mantra 3 Surgical Robotic System
GlobeNewswire
·
July 10, 2025
Led by Dr. Mohit Bhandari, a pioneer in bariatric surgery and President of the Institute of Research Against Digestive Cancer (IRCAD) India, the surgery was remotely performed at a distance of 560 miles and executed on-site at Mohak Bariatric …
The International Myeloma Foundation’s Brian D. Novis Research Grants: Celebrating 30 Years of Paving the Way for Transformative Breakthroughs in Myeloma Research
GlobeNewswire
·
July 10, 2025
STUDIO CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) is proud to announce the 30th anniversary of the Brian D. Novis (BDN) Research Grant Program. To honor the memory of its co-founder, the Brian D. Novis …
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer Treatment
GlobeNewswire
·
July 10, 2025
NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio@IBN ( …
Dentsply Sirona to Host Second Quarter Conference Call on August 7th
GlobeNewswire
·
July 10, 2025
CHARLOTTE, N.C., July 10, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will host an investor conference call and live webcast on Thursday, August 7, 2025, at 8:30 am ET …
Intelligent Bio Solutions to Present PK Study Data at Association for Diagnostics and Laboratory Medicine 2025 Clinical Lab Expo
GlobeNewswire
·
July 10, 2025
Data shows excretion of codeine in fingerprint sweat INBS’ System is viable option for non-invasive diagnostic testing NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology …
OSS Announces $2 Million Follow-On Production Order from Innovative Medical Imaging OEM
GlobeNewswire
·
July 10, 2025
ESCONDIDO, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- One Stop Systems, Inc. (OSS or the Company) (Nasdaq: OSS), a leader in rugged Enterprise Class compute for artificial intelligence (AI), machine learning (ML) and sensor processing at the edge, today …
e-therapeutics De-risks Clinical Path for GalOmic Candidate ETX-312 with Positive Non-clinical Data
GlobeNewswire
·
July 10, 2025
ETX-312 well tolerated at exaggerated dose levels in GLP-compliant toxicology studies GMP manufacturing of clinical trial batch successfully completed On track for CTA submission in Q4 2025 LONDON, July 10, 2025 (GLOBE NEWSWIRE) -- e-therapeutics plc, a …
PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results
GlobeNewswire
·
July 10, 2025
PRINCETON, N.J., July 10, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced …
Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference
GlobeNewswire
·
July 10, 2025
BOTHELL, Wash., July 10, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that its first-in-class pan-viral protease inhibitor CDI-988 has been selected for an oral presentation at the 9th International Calicivirus Conference being …
Pelthos Therapeutics Launches ZELSUVMI™ (berdazimer) Topical Gel 10.3%, the First and Only FDA-Approved At-Home Treatment for Molluscum Contagiosum
GlobeNewswire
·
July 10, 2025
ZELSUVMI is now commercially available via prescription through retail pharmacies, ASPN pharmacy services and for at-home delivery through mail-order pharmacies Once-daily topical prescription medication can be applied by patients, parents and caregivers …
Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer’s Association International Conference (AAIC®) 2025
GlobeNewswire
·
July 10, 2025
NEWTON, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s …
Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™
GlobeNewswire
·
July 10, 2025
JUPITER, Fla., July 10, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Pelthos Therapeutics Inc. (NYSE American: PTHS) has commercially launched ZELSUVMI™ (berdazimer) topical gel 10.3%, the …
TerrAscend to Host Second Quarter 2025 Earnings Conference Call
GlobeNewswire
·
July 10, 2025
TORONTO, July 10, 2025 (GLOBE NEWSWIRE) -- TerrAscend Corp. ("TerrAscend" or the "Company") (TSX: TSND) (OTCQX: TSNDF), a leading North American cannabis company, today announced that it will host a scheduled conference call to discuss the results for its …
Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
GlobeNewswire
·
July 10, 2025
ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) NEW YORK and NORTH CHICAGO, Ill., July 10, 2025 (GLOBE NEWSWIRE) -- IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos …
Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer’s Disease
GlobeNewswire
·
July 10, 2025
PURCHASE, N.Y., July 10, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, conducted an end-of-Phase 2 meeting with the U.S. …
Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference
GlobeNewswire
·
July 10, 2025
The Joint Society for Neuro-Oncology (SNO) and the American Society of Clinical Oncology (ASCO) focus on the rapidly evolving area of central nervous system metastases Presentations will highlight the clinical utility of the company’s CNSide Cerebrospinal …
BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient
GlobeNewswire
·
July 10, 2025
[IMAGES BELOW] Sustained complete resolution of temporal lobe brain metastasis and continued orbital tumor reduction after >18 months of treatment “Eye bulging” metastatic breast cancer patient had failed 8 prior regimens, including antibody-drug conjugate …
AMN Healthcare to Hold Second Quarter 2025 Earnings Conference Call on Thursday, August 7, 2025
GlobeNewswire
·
July 10, 2025
DALLAS, July 10, 2025 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), has scheduled a conference call to discuss its second quarter 2025 financial results and third quarter 2025 outlook on Thursday, August 7, 2025, at 5:00 p.m. Eastern Time. …